slides · global inventory
Diagram
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 23,622
Current window 16,711-16,740
Pages 788
Rows per page 30
Component
16,711-16,740 of 23,622
56
Includes comparative size diagram of IMX-111 vs IgG antibody, bar chart of GLUT1 expression by tissue, box plot of GLUT1 expression by stage, and Kaplan-Meier survival curve.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
58
Includes multiple citations and diagrams of molecular mechanism and clinical trial results.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
62
The process is presented as a non-linear, snake-like flow (1-5 left-to-right, 6-10 right-to-left).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
07
The central diagram is a pyramid structure representing Intellectual Capital as the foundation of the four pillars.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
18
The slide uses a split-layout: a table for AUM breakdown by asset class on the left and a timeline of team additions on the right.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · TeamLoop · Hypothesis Test1 hit
21
The central diagram uses a hub-and-spoke layout to represent the interconnected nature of the advisory services.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations 1 hit
25
The slide uses a process diagram to show the evolution of funding stages and a pie chart to represent the $11T AUM market.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations 1 hit
26
The slide uses a circular diagram to map 'Solutions' to 'Applications' in capital markets.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations 1 hit
28
The diagram uses a hub-and-spoke circular flow model to represent capital allocation.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · Financials1 hit
36
The slide uses a standard ESG framework to categorize corporate initiatives and business-specific integration strategies.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations 1 hit
08
The slide uses a combination of a circular hub-and-spoke style grouping for core strategies and a linear process flow for R&D stages.Legend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations Beat · Solution1 hit
09
The slide combines a geographic split visualization with a chronological milestone payment tracker.Legend Biotech | Investor Presentation Deck | 14 slides · Legend Biotech
Conference presentation Investor relations 1 hit
15
The slide highlights a strategy of inorganic growth through targeted acquisitions of film libraries and production companies.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Loop · Cost Of Inaction1 hit
17
The slide uses a stepped pillar visualization to represent strategic assets.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Loop · Cost Of Inaction1 hit
19
The slide uses a flow-based diagram to show asset contributions and equity stakes.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · The AskLoop · Why Now1 hit
11
The slide outlines a multi-part clinical trial process from Part A (Safety) through Part B (Efficacy/Dose Selection) to a planned Expansion phase.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
The slide outlines a multi-part clinical trial design (basket/umbrella) for a biotech drug candidate.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
22
The slide outlines a clinical trial process flow involving SCLC and NSCLC patient baskets, immune activation, and subsequent combination therapies leading to a Phase 3 expansion.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
12
The slide highlights the integration of mRNA and DNA biomarkers into a proprietary algorithm for colorectal cancer (CRC) and advanced adenoma (AA) detection.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
13
Mainz Biomed NV | Investor Presentation Deck | 24 slidesMainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
17
The slide uses a horizontal timeline format to map product milestones against calendar years.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
The slide uses a two-part framework: Targeting (left) and Delivery (right).Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
09
The slide uses a process flow diagram to map clinical outcomes to specific trial metrics.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a timeline-based case study format to demonstrate clinical efficacy and safety.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
16
The slide outlines the randomization, treatment arms, timeline, patient population criteria, and primary/secondary endpoints.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
20
Uses a chevron-based process flow to represent maturity stages.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
22
The slide uses a timeline diagram to explain the experimental design and a line chart to show tumor volume reduction over time.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
06
The central hub is 'Accelerate Product Development', surrounded by four strategic pillars, each with a corresponding icon.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit